This invention is related to a phytotherapic composition associated to polyvitamin and mineral supplements for anti-hepatotoxic and antioxidant treatment, besides helping hepatic protein synthesis and the circulatory system and contributing directly to neurotransmitter synthesis, whereby its hepatoprotective action helps patients with liver diseases or developing hepatobiliary disorders, providing relief in dyspepsia and liver-related digestive problems.

This invention is related to a phytotherapic composition associated to polyvitamin and mineral supplements for anti-hepatotoxic and antioxidant treatment, besides helping hepatic protein synthesis and the circulatory system and contributing directly to neurotransmitter synthesis, whereby its hepatoprotective action helps patients with liver diseases or developing hepatobiliary disorders, providing relief in dyspepsia and liver-related digestive problems.

This invention is related to a phytotherapic composition associated to polyvitamin and mineral supplements for anti-hepatotoxic and antioxidant treatment, besides helping hepatic protein synthesis and the circulatory system and contributing directly to neurotransmitter synthesis, whereby its hepatoprotective action helps patients with liver diseases or developing hepatobiliary disorders, providing relief in dyspepsia and liver-related digestive problems.

The disclosure provides methods of modulating an immune response by inhibiting BFL1, and related methods for treating and preventing diseases and disorders characterized by inflammation, especially neutrophil induced inflammation.

The present invention includes compositions and methods for the treatment or prevention of a disease or condition that causes dry eyes comprising: an effective amount of at least two active agents selected from: (1) at least one cholinesterase inhibitor; (2) at least one form of choline; (3) at least one form of carnitine; (4) at least one form of muscarinic agonist, sufficient to treat the disease or condition that causes dry eyes.

The present invention includes compositions and methods for the treatment or prevention of a disease or condition that causes dry eyes comprising: an effective amount of at least two active agents selected from: (1) at least one cholinesterase inhibitor; (2) at least one form of choline; (3) at least one form of carnitine; (4) at least one form of muscarinic agonist, sufficient to treat the disease or condition that causes dry eyes.

The invention provides the use of a formulation containing cyclodextrin, quercetin and zinc at appropriate concentrations to mitigate infections by enveloped viruses. While the different forms of cyclodextrin prevent the entry of coated viruses into host cells by extracting and sequestering cholesterol molecules at the virus envelope and at the host cell plasma membrane, the ionophore quercetin enables cellular entry of zinc, thereby inhibiting viral replication by altering polymerase activity in the host cell.

The invention provides the use of a formulation containing cyclodextrin, quercetin and zinc at appropriate concentrations to mitigate infections by enveloped viruses. While the different forms of cyclodextrin prevent the entry of coated viruses into host cells by extracting and sequestering cholesterol molecules at the virus envelope and at the host cell plasma membrane, the ionophore quercetin enables cellular entry of zinc, thereby inhibiting viral replication by altering polymerase activity in the host cell.

The invention provides the use of a formulation containing cyclodextrin, quercetin and zinc at appropriate concentrations to mitigate infections by enveloped viruses. While the different forms of cyclodextrin prevent the entry of coated viruses into host cells by extracting and sequestering cholesterol molecules at the virus envelope and at the host cell plasma membrane, the ionophore quercetin enables cellular entry of zinc, thereby inhibiting viral replication by altering polymerase activity in the host cell.

The present invention relates to methods and compositions for enhancing expression from RNA expression vectores. The invention is based upon the observation that reducing the frequency of the dinucleotide CpG and UpA has a significant effect on expression from such vectores. Aspects of the invention include, amongst others, synthetic RNA vectores, virions, cells, methods of producing vaccines and methods of treatment or immunisation.